Latest Liquidity News

WAM Alternative Assets reported modest profit growth for FY2025, raised its fully franked final dividend by 15.4%, and outlined a strategic shift towards growth investments in its diversified alternative assets portfolio.

Kalina Power Limited reported a net loss of AUD 4.67 million for FY25 with no revenue generated, while pursuing strategic asset sales and capital raising amid going concern uncertainties.

Advanced Braking Technology Ltd reported a robust 25% revenue increase and a 36% rise in net profit for FY25, driven by international expansion and new product launches.

Advanced Braking Technology Ltd (ASX, ABV) reported a robust 25% revenue increase and 36% net profit growth for FY25, driven by international expansion and pioneering product launches in mining safety technology.

Helix Resources Limited’s HLXOA securities have been suspended from trading pending regulatory compliance, raising questions about the company’s immediate outlook.

Nickel Industries reported a robust 81% rise in half-year profit to US$25.5 million, while advancing the Excelsior Nickel Cobalt project towards commissioning. The company also declared a final dividend and highlighted sustainability achievements.

Cyprium Metals has secured A$80 million through a placement and entitlement offer to fund the restart of its Nifty Copper Complex and reduce existing debt, backed by strong institutional support.

betr Entertainment Limited marked a transformative FY25 with a successful merger, strategic acquisitions, and a sharp reduction in losses, setting the stage for a major takeover bid of PointsBet.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

De.mem Limited reported a 19.7% increase in revenue to $13.96 million for the half-year ended June 2025, alongside a 42% reduction in net loss and its first positive adjusted EBITDA in years. Strategic acquisitions and expansion into Asian domestic markets underpin the company’s improving financial health.